Moderna chooses Harwell Campus as site for UK research facility
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) said in a tweet on Monday that it has chosen Harwell Campus in Oxfordshire as the place for its Moderna Innovation and Technology Centre (MITC) in the U.K.
The mRNA-based COVID vaccine maker added that this milestone follows finalization of the company's 10-year strategic partnership with the U.K. government in December 2022.

Under the partnership Moderna planned to set up an mRNA research, development, and manufacturing facility in the UK.
The MITC is aimed to provide access to a domestically manufactured portfolio of future mRNA vaccines against respiratory viruses, upon approval.
In addition, the facility is aimed at helping UK with direct access to pandemic response capabilities, which will support the country in its global efforts as part of its "100 Days Mission" to reduce the impact of future pandemics.